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Polyamine biosynthesis and function has been shown to be a good drug target in some parasitic protozoa
and it is proposed that the pathway might also represent a target in the malaria parasite Plasmodium
falciparum. A series of 1,3,5-triazine-substituted polyamine analogues were tested for activity against Plas-
modium falciparum in vitro. The series showed activity against the parasites and were generally more active
against the chloroquine-resistant line K1 than the chloroquine-susceptible line NF54. Simple unbranched
analogues had better activity than analogues carrying branched or cyclic central chains. Addition of multi-
ple triazine units in general led to increased activity of the compounds.
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Introduction
Malaria remains one of the principal diseases of the developing world
with an estimated 500 million cases each year and around two million
deaths.1 In the absence of effective vaccines, chemotherapy rep-
resents the mainstay of malaria control. Resistance to currently used
antimalarials, particularly chloroquine and the antifolates, is seriously
impeding efforts to control the disease.2 New drugs are urgently
needed in the fight against malaria. Polyamine metabolism has been
shown to be a good target for chemotherapeutic intervention in
diseases caused by other protozoa such as human African trypano-
somiasis,3 where the ornithine decarboxylase inhibitor eflornithine
has been registered for use against late-stage disease.4
Polyamines are essential for cell proliferation and differentiation.
Interference with their biosynthesis or function can block cellular
growth and the polyamine pathway has been investigated with regard
to anticancer therapy.5 Malaria parasites have a great propensity for
rapid proliferation, and interference with polyamine function in these
cells is likely to be detrimental. Eflornithine, used in conjunction with
bis(benzyl)polyamine analogues, cured rodent malaria models,6
although used alone eflornithine has no curative affect in human
malaria. An S-adenosylmethionine decarboxylase inhibitor, methyl-
glyoxalbis(guanyl) hydrazone (MGBG), blocked growth of the
erythrocytic stages of Plasmodium falciparum in vitro.7 Moderate
antiplasmodial activity was also seen with a series of N-alkylated
putrescine derivatives,8 and dicyclohexylamine, an inhibitor of
spermidine biosynthesis, also showed antiplasmodial activity.9
We previously reported a series of 1,3,5-triazine-substituted
polyamine analogues, which were developed specifically to interfere
with polyamine metabolism in African trypanosomes.10 Several of
the compounds showed marked trypanocidal activity. We report here
the evaluation of the activity of this series against P. falciparum in
vitro.
Materials and methods
The syntheses of the compounds has been reported previously.10 In vitro
activity against erythrocytic stages of P. falciparum was determined
using a [3H]hypoxanthine incorporation assay.11,12 One strain suscep-
tible to known antimalarial drugs (P. falciparum NF54) and another
resistant to chloroquine and pyrimethamine (P. falciparum K1) were
used in the assays, and all test compounds were compared for activity
with the standard drugs chloroquine (Sigma C6628) and artemisinin
(arteannuin, qinghaosu; Sigma 36,159-3). Compounds were dissolved
in dimethyl sulfoxide at 10 mg/mL and added to parasite cultures
incubated in RPMI 1640 medium without hypoxanthine, supplemented
with HEPES (5.94 g/L), NaHCO3 (2.1 g/L), neomycin (100 U/mL) +
Albumax (5 g/L) and washed human red cells A+ at 2.5% haematocrit
(0.3% parasitaemia). Serial doubling dilutions of each drug were prepared
in 96-well microtitre plates and incubated in a humidifying atmosphere at
37°C; 4% CO2, 3% O2, 93% N2.
After 48 h, 50 µL of [3H]hypoxanthine (0.5 µCi) was added to each
well of the plate. The plates were incubated for a further 24 h under the
same conditions. The plates were then harvested with a Betaplate cell
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harvester (Wallac, Zurich, Switzerland), and the red blood cells were
transferred onto a glass fibre filter and then washed with distilled water.
The dried filters were inserted into a plastic foil with 10 mL of scintil-
lation fluid, and counted in a Betaplate liquid scintillation counter
(Wallac). IC50 values were calculated from sigmoidal inhibition curves
using Microsoft Excel.
Results
The structures of the compounds are shown in Figure 1. Compounds
were tested against two strains of P. falciparum. The strains used
were NF54, which is susceptible to known antimalarial drugs, and
K1, which is resistant to chloroquine and pyrimethamine (Table 1).
Compounds were generally more active against the resistant K1
strain than against the susceptible NF54 strain. For simple substituted
derivatives, compound 1, activity increased as the length of the
central chain increased in the order butyl < nonyl < dodecyl.
Branched chain and cyclic central chains had little activity. No major
effect was noted on increasing the methylation of the triazine ring for
compounds 2a–d and 2e–h. However, against NF54 strain, there was
a small increase in activity on methylation, whilst for the K1 strain,
there is a small decrease in activity on methylation. No major effect
was seen on having one triazine unit compared with two. In general
the polyamines substituted with one triazine appeared less active than
those substituted with two triazines (comparing 2e–h with 3b–e). The
Figure 1. Structures of the 1,3,5-triazine-substituted polyamines used in this study.
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most effective compounds were tetra-substituted methylene-bridged
compounds 4, especially where they were methylated. These com-
pounds also showed best activity against Trypanosoma brucei.10
In vitro data did not point to cytotoxicity; however, acute toxicity,
manifest in muscular tremor, motor-function disorder and distress
that necessitated immediate killing of the animal was observed when
compounds 2e, 4b, 4c or 4e were applied to mice at concentrations
>10 mg/kg, precluding further in vivo evaluation. Thus in this case,
the cellular assay was not a good indicator of toxicity towards the
animal. The toxicity may be caused by an effect on a specific signally
event or receptor, rather than general cytotoxicity.
Discussion
In this report we show that triazine-substituted polyamine analogues
have antiplasmodial activity against erythrocytic stages of the para-
site in vitro. It was previously shown6 that bis(benzyl) polyamine
analogues had activity against malaria parasites in the 0.2–14 µM
range, and we demonstrate here that these triazine-substituted com-
pounds are also active in this range. N-alkyl putrescine derivatives
have also been shown to be weakly active against Plasmodium,
although benzyl derivates were shown to give improved activity in
this case as well. Interestingly, chloroquine/pyrimethamine-resistant
parasites are more susceptible to these analogues than are susceptible
parasites; however, we have not made mechanistic studies that can be
used to help interpret this observation. In another study evaluating the
effects of spermidine biosynthesis inhibition,9 data were presented
showing a 3-fold higher spermidine content in wild-type NF54
parasites compared with a chloroquine-resistant strain. If polyamine
deficiency were a common phenotype of chloroquine-resistant lines
this could explain the enhanced susceptibility of these cells to poly-
amine analogues, which might act by displacing polyamines from
their normal roles in cells.
However, it is currently not clear how these triazine-substituted
polyamine analogues actually exert their action. In rodents, Plasmo-
dium yoelii-infected erythrocytes have been shown to have enhanced
polyamine uptake.13 The parasites may induce specific transporters
for these metabolites and Plasmodium knowlesi-infected erythro-
cytes have been shown to have an up-regulated putrescine-specific
uptake system.14 It is also possible that the triazine-substituted
analogues are preferentially taken into Plasmodium-infected erythro-
cytes via the new permeation pathway that is induced at the plasma
membrane of infected erythrocytes.15 It will be of interest to deter-
mine how these analogues enter infected erythrocytes and exert a
toxic effect on the parasites. We cannot rule out the possibility that
the compounds are oxidized by serum components prior to exerting a
toxic effect. Interestingly, it has recently been shown that penta-
midine and other diamidine compounds are active against malaria
parasites grown in vitro,16 with efficacy in the submicromolar range.
It has been proposed that diamidines exert their plasmocidal effect by
binding to ferriprotoporphyrin IX and preventing the polymerization
of haem that accumulates to toxic levels in these parasites. It is feas-
ible that the triazine-substituted polyamine analogues could act in a
similar fashion. Further work is required to elucidate modes of action
of these compounds.13
Acknowledgements
The technical assistance of C. Scheurer and J. Easterbrook is
acknowledged. We would also like to acknowledge the Wellcome
Trust and the UNDP/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases (TDR) for funding.
References
1. Greenwood, B. & Mutabingwa, T. (2002). Malaria in 2002. Nature
415, 670–2.
2. Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. et al.
(2002). Epidemiology of drug-resistant malaria. Lancet Infectious Dis-
eases 2, 209–18.
3. Laurence, J., Marton, L. J. & Pegg, A. E. (1995). Polyamines as
targets for therapeutic intervention. Annual Review of Pharmacology and
Toxicology 35, 55–91.
4. Bacchi, C. J., Nathan, H. C., Hutner, S. H. et al. (1980). Polyamine
metabolism: a potential therapeutic target in trypanosomes. Science 210,
332–4.
5. Barrett, S. V. & Barrett, M. P. (2000). Anti-sleeping sickness drugs
and cancer chemotherapy. Parasitology Today 16, 7–9.
6. Bitonti, A. J., Dumont, J. A., Bush, T. L. et al. (1989).
Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant
human malaria parasites (Plasmodium falciparum) in vitro and in
Table 1. Antimalarial activity of compounds against NF54 and 
K1 strains of P. falciparum
ND, not determined.
a3b contains ∼10% of bis-adduct 2e.
b3c contains ∼15% of bis-adduct 2f.
The IC50 values are the means of four values of two independent assays
carried out in duplicate. They were determined by linear interpolation
between the two adjacent drug concentrations above and below the 50%
incorporation line.
Compound
NF54 K1 L6 rat myoblast cells
IC50 (µM) IC50 (µM) IC50 (µM)
1a >17.6 >8.80 353
1b 4.383 0.155 ND
1c 0.618 0.142 295
1d >18.1 >18.1 362
1e >16.9 >16.9 338
1f >16.9 >16.9 338
2a 3.95 0.216 285
2b 1.93 0.410 274
2c 1.49 0.291 289
2d 0.579 0.745 37.7
2e 0.809 0.229 ND
2f 0.149 0.244 0.9
2g 0.470 0.372 143
2h 0.173 0.335 6.8
3a 0.582 0.180 135.2
3ba 2.033 0.408 127
3cb 0.618 0.743 39.9
3d 1.724 0.391 57.7
3e 0.831 0.450 14.2
4a >7.5 >7.5 220
4b 0.164 0.135 177
4c 0.072 0.154 177
4d 1.563 0.747 188
4e 0.0698 0.0622 105
4f 0.0477 0.0519 76.6
Antiplasmodial activity of 1,3,5-triazine-substituted polyamines
293
combination with alpha-difluoromethylornithine cure murine malaria. Pro-
ceedings of the National Academy of Sciences, USA 86, 651–5.
7. Wright, P. S., Byers T. L., Cross-Doersen, D. E. et al. (1991). Irre-
versible inhibition of S-adenosylmethionine decarboxylase in Plasmodium
falciparum-infected erythrocytes: growth inhibition in vitro. Biochemical
Pharmacology 41, 1713–8.
8. Slater, L. A., McMonagle, F. A., Phillips, R. S. et al. (1998). Anti-
malarial activity of unsaturated putrescine derivatives. Annals of Tropical
Medicine and Parasitology 92, 271–7.
9. Kaiser, A., Gottwald, A., Wiersch, C. et al. (2001). Effect of drugs
inhibiting spermidine biosynthesis and metabolism on the in vitro develop-
ment of Plasmodium falciparum. Parasitology Research 87, 963–72.
10. Klenke, B., Stewart, M., Barrett, M. P. et al. (2001). Synthesis and
biological evaluation of s-triazine substituted polyamines as potential
new anti-trypanosomal drugs. Journal of Medicinal Chemistry 44, 3440–52.
11. Desjardins, R. E., Canfield, C. J., Haynes, D. et al. (1979). Quan-
titative assessment of antimalarial activity in vitro by a semiautomated
microdilution technique. Antimicrobial Agents and Chemotherapy 16,
710–8.
12. Matile, H. & Pink, J. R. L. (1990). Plasmodium falciparum malaria
parasite cultures and their use in immunology. In Immunological Methods
(Lefkovits, I. & Pernis, B., Eds), pp. 221–34. Academic Press, San Diego,
CA, USA.
13. Muller, S., Coombs, G. H. & Walter, R. D. (2001). Targeting
polyamines of parasitic protozoa in chemotherapy. Trends in Parasitology
17, 242–9.
14. Singh, S., Puri, S. K., Singh, S. K. et al. (1997). Characterization of
simian malarial parasite (Plasmodium knowlesi)-induced putrescine
transport in rhesus monkey erythrocytes. A novel putrescine conjugate
arrests in vitro growth of simian malarial parasite (Plasmodium knowlesi)
and cures multidrug resistant murine malaria (Plasmodium yoelii) infec-
tion in vivo. Journal of Biological Chemistry 272, 13506–11.
15. Kirk, K., Staines, H. M., Martin, R. E. et al. (1999). Transport pro-
perties of the host cell membrane. Novartis Foundation Symposium 226,
55–66; discussion 66–73.
16. Stead, A. M., Bray, P. G., Edwards, I. G. et al. (2001). Diamidine
compounds: selective uptake and targeting in Plasmodium falciparum.
Molecular Pharmacology 59, 1298–306.
